Diving Into Diabetes

About Diving Into Diabetes

The world of diabetes management is constantly evolving, with new research, new treatments, and new recommendations for best practice. Diving into Diabetes is a series of in-depth conversations with experts who are on the front lines of diabetes research and management. We're starting the conversation with those who are committed to improving and individualizing diabetes treatment to help provide important information and insight for fellow healthcare professionals keen to target the needs of their patients. This podcast is intended for healthcare professionals only. Speaker disclosures are available in each episode’s notes. The views and opinions expressed in this program are those of the speakers and do not necessarily reflect the views or positions of any entities they represent. Some information contained herein may cite the use of an unapproved product in a dosage, for an indication, or in a manner other than recommended. Before prescribing any product, always refer to the latest Product Monograph. Financial support for the Diving Into Diabetes program was provided by Sanofi Canada. MAT-CA-2200968

Publisher

Diving Into Diabetes

Category

health & fitness · science

Language

en

Explicit

No

First episode

8 Sept 2022

Latest episode

3 Sept 2026

Latest episodes

29 episodes in the feed.

1. 

   3 Sept 2026

   The shift to a new era in Type 1 diabetes management

   How can emerging disease-modifying therapies reshape the trajectory of type 1 diabetes? In this episode, our host, Dr. Alice Cheng, discusses the cutting-edge landscape of type 1 diabetes (T1D) prevention and intervention with Dr. Bruce Perkins, endocrinologist, epidemiologist, clinician-scientist, and professor in the Faculty of Medicine and the Institute for Health Policy, Management and Evaluation at the University of Toronto. Join our experts as they explore how T1D care is shifting from symptom management through insulin replacement toward early intervention in a disease that develops silently over years. Discover the clinical benefits of early disease modification and the transformative potential of novel therapeutic targets in delaying T1D onset and preserving beta-cell function. Learn about the practical mechanics of emerging therapies, where they precisely target the immune system, and how clinicians can take practical steps to screen, identify, and intervene before clinical symptoms or hyperglycemia present. Tune in as we discuss the future of T1D care, exploring how population-wide screening and precision biomarker matching are actively bridging the critical gap between groundbreaking research and its clinical application. Don't miss this discussion! The opinions and views expressed in this episode are those of the speakers and do not necessarily reflect the position of the entities they represent. Declaration of conflict of interest: Dr. Alice Cheng: Direct financial links, including receipt of fees: Abbott, Amgen, Aspen, Astellas, AstraZeneca, Bausch, Bayer, Biomea, Boehringer Ingelheim, Caliway Biopharmaceutics, Dexcom, Eisai, Eli Lilly, Gan & Lee, Insulet, HLS Therapeutics, Medtronic, Merck, MSD, Novo Nordisk, Sandoz, Sanofi, Vertex, CPD Network, Canadian Collaborative Research Network, Master Clinical Alliance, Canadian Medical & Surgical Knowledge Translation Research Group, Sea Courses, Alliance of Best Practices in Health Education, Partners in Progressive Medical Education, MDBriefCase, LMC Physician Inc., Medscape, Humber River Health, TimedRight, International Atherosclerosis Society, Canadian Cardiovascular Society, Diabetes Canada, American Diabetes Association, The Rounds, PeerVoice, Virtual Hallway, Diversified Canada. Advisory Committee or Speaker Bureau Members: Abbott, Amgen, Aspen, Astellas, AstraZeneca, Bausch, Bayer, Biomea, Boehringer Ingelheim, Caliway Biopharmaceuticals, Dexcom, Eisai, Eli Lilly, Gan & Lee, Insulet, HLS Therapeutics, Medtronic, Merck, MSD, Novo Nordisk, Sandoz, Sanofi, Vertex. Funded grants, research, or clinical trials: Applied Therapeutics, Novo Nordisk, Sanofi. Dr. Bruce Perkins: Direct financial links, including receipt of fees: Abbott, Dexcom, Insulet NovoNordisk, Sanofi. Advisory Committee or Speaker Bureau Members: Abbott, Dexcom, Insulet, Nephris NovoNordisk, Sanofi, Vertex. Funded grants, research, or clinical trials: NIH-NIDDK, Diabetes Canada. MAT-CA-2601068

2. 

   25 Jun 2026

   The hypoglycemia safety net: updated recommendations to optimize patient outcomes

   Managing hypoglycemia remains a persistent, high-stakes challenge for both clinicians and the patients they support. What are the updates to the Diabetes Canada Clinical Practice Guidelines for Hypoglycemia and how can these be integrated into daily practice immediately? Our host, Dr. Jeremy Gilbert, an Endocrinologist at Sunnybrook Health Sciences Centre and Associate Professor at the University of Toronto, discusses standardizing hypoglycemia safety with Dr. Akshay Jain, a Clinical Endocrinologist and Medical Director for Research at Unity Healthcare based in Surrey, British Columbia. Together, our experts explore the complex clinical realities and systemic gaps surrounding hypoglycemia management. They discuss the practical implications of the updated Diabetes Canada guidelines, detailing the new three-level classification of hypoglycemia, and the symptoms associated with each level. They highlight the importance of prevention, strategies for monitoring, and important conversations to have with patients about hypoglycemia. Tune in to hear practical, actionable tips for managing hypoglycemia to better support individuals living with diabetes. Don’t miss the conversation! The views and opinions expressed in this episode are those of the speakers, and do not necessarily reflect the views or positions of any entities they represent. Declaration of conflict of interest: Dr. Jeremy Gilbert: Direct financial relationship, including receipt of honoraria: CPD Network, LMC Canada Inc., CSEM, S+L Solutions, Liv Agency, Unik Agency, STA. Membership on advisory boards or speaker’s bureaus: Abbott, Amgen, Bayer, Insulet, Tandem, Boehringer Ingelheim, Eli Lilly, GSK, HLS Therapeutics, Novartis, Novo Nordisk. Dr. Akshay Jain: Direct financial relationship, including receipt of honoraria: Abbott, Abbvie, AstraZeneca, Amgen, Antibody, Bausch Healthcare, Bayer, Boehringer Ingelheim, Care to Know, CCRN, Connected in Motion, CPD Network, Dexcom, Diabetes Canada, Eli Lilly, Embecta, EOCI, GSK, HLS Therapeutics, Janssen, Liv, Master Clinician Alliance, MDBriefcase, Merck, Medtronic, Moderna, NP Circle, Novartis, Novo Nordisk, Partners in Progressive Medical Education, Pfizer, Roche, Six Degrees, Timed Right, Unik, WebMD. Membership on advisory boards or speaker’s bureaus: Abbott, AstraZeneca, Amgen, Bausch Healthcare, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Embecta, Gilead Sciences, GSK, HLS Therapeutics, Industrii, Insulet, Janssen, Medtronic, NP Circle, Novartis, Novo Nordisk, Partners in Progressive Medical Education, Pendopharm, PocketPills, Roche, Sandoz, Takeda, Ypsomed. Funded grants, research, or clinical trials: Abbott, Amgen, Argenx, Astra Zeneca, Novo Nordisk, Roche, Sanofi. MAT-CA-2600837

3. 

   17 Jun 2026

   Early Identification of T1D: Practical Considerations for Implementation in Clinical Practice

   What is the role of early detection of type 1 diabetes and how can it be integrated into clinical practice? In this episode, our host, Dr. Maha Lebbar, discusses the practical aspects of screening for type 1 diabetes (T1D) with Dr. Rémi Rabasa-Lhoret, endocrinologist at Centre Hospitalier de L’Université de Montréal (CHUM), professor and researcher at the Montréal Clinical Research Institute (IRCM). Join our experts as they discuss the clinical benefits of early T1D identification and the transformative potential of early interventions in improving long-term health outcomes and preventing severe complications. Learn about the practical steps and options for T1D screening, gaining in-depth insights into various screening pathways, existing programs, and promising research initiatives driving innovation in this field. Tune in as we explore how studies such as FEDERATE Can are actively bridging the critical gap between research and its practical application in clinical settings. Discover concrete recommendations for healthcare providers to integrate early detection of T1D into their everyday practice, including workflow considerations for screening, monitoring, and follow-up. Don't miss this discussion! The opinions and views expressed in this episode are those of the speakers and do not necessarily reflect the position of the entities they represent. Declaration of conflict of interest: Dr Maha Lebbar: Direct financial links, including receipt of fees: Sanofi. Receipt of grants or funding for research projects or clinical trials: Sanofi. Dr Rémi Rabasa-Lhoret: Direct financial links, including receipt of fees: Abbott, CPD Network, Dexcom, Eli Lilly, Janssen, Medtronic, Merck, Novo Nordisk, Sanofi, Tandem Diabetes Care, Vertex Pharmaceuticals. Advisory Committee or Speaker Bureau Members: 35Pharma Inc., Abbott, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, GlaxoSmithKline Inc., HLS Therapeutics, INESSS, Insulet, Medtronic, Merck, Novo Nordisk, Sanofi, Ypsomed. Receipt of grants or funding for research projects or clinical trials: Diabetes Canada, Cystic Fibrosis Canada, Canadian Institutes of Health Research (CIHR), Diabetes Research Foundation (JDRF), Novo Nordisk, Société francophone du diabetes, Medtronic, Merck, Sanofi. Patents relating to a medicine, product or medical device: Eli Lilly. MAT-CA-2200968

Reach and audience

Public platform figures. Ratings count people who left a rating, not total listeners.

Apple Podcasts (US)

5.0 / 5

1 ratings

Spotify

5.0 / 5

3 ratings